Active Pharmaceutical Ingredients - Dr Reddy's
Active Pharmaceutical Ingredients - Dr Reddy's

关于 Relugolix API

Product
  • CAS 编号

    737789-87-6

  • API 技术

    合成

  • 剂型

    口服固体/片剂, 注射剂

  • Dr Reddy's 开发状态

    可用的

  • 可用的法规申报文件

    USDMF, 巴西 DMF

作用机制

瑞鲁戈利是一种非肽类促性腺激素释放激素受体拮抗剂,通过竞争性结合垂体促性腺激素释放激素受体,从而减少促黄体生成激素(LH)和促卵泡激素(FSH)的释放,进而降低睾酮水平。

适应症

ORGOVYX 是一种促性腺激素释放激素(GnRH)受体拮抗剂,用于治疗晚期前列腺癌成人患者。

Dr. Reddy's的专长

瑞迪博士实验室(Dr. Reddy’s)总部位于印度海得拉巴,是全球领先的原料药(API)供应商之一。瑞迪博士的 API 业务是美国、欧洲、巴西、拉丁美洲、日本、中国、韩国及新兴市场制药公司的首选合作伙伴。

过去 30 年来,瑞迪博士 API 业务依托在复杂原料药研发与制造方面建立的深厚技术基础持续发展,涵盖类固醇、肽类、复杂长链分子以及高效原料药(HPAPI/肿瘤药物)等领域。我们在知识产权和法规事务方面的优势与上述技术实力相辅相成,使我们能够持续满足并超越全球监管标准。**瑞迪博士的瑞鲁戈利原料药(Relugolix API)**正是我们在研发、知识产权及法规合规方面深厚经验的成果。

帮助客户保持竞争优势的关键因素之一是高响应性的供应链体系。我们通过确保所有生产设施高效运行,并符合最新的质量、安全和生产力标准来实现这一目标。运营与各生产基地之间的高度互联,使我们能够快速应对不断变化的市场需求,有效避免供应短缺,并及时满足突发性的需求增长。

瑞迪博士实验室是一家瑞鲁戈利(Relugolix)原料药制造商,致力于为客户提供稳定、可靠的 API 供应。我们的瑞鲁戈利原料药按照最高质量标准进行生产。

如需了解瑞迪博士作为瑞鲁戈利原料药制造商的更多能力与信息,欢迎联系我们:[email protected]


 

Request for Quotation

Get in touch with us by filling out the form below. Our team will reach out to you shortly!

Phone
Country *
Select Product *
Select Regulatory Requirements
Select Purpose

Related APIs

Zoledronic Acid(唑来膦酸)

Oncology(肿瘤)

arrow

Dasatinib Monohydrate(达沙替尼一水合物)

Oncology(肿瘤)

arrow

Adagrasib(阿达格拉西布)

Oncology(肿瘤)

arrow

Bendamustine Hydrochloride(盐酸苯达莫司汀)

Oncology(肿瘤)

arrow

Fruquintinib(呋喹替尼)

Oncology(肿瘤)

arrow

Venetoclax(维奈托克)

Oncology(肿瘤)

arrow

Tucatinib(图卡替尼)

Oncology(肿瘤)

arrow

Ripretinib(瑞派替尼)

Oncology(肿瘤)

arrow

Abiraterone Acetate(醋酸阿比特龙)

Oncology(肿瘤)

arrow

Azacitidine(阿扎胞苷)

Oncology(肿瘤)

arrow

Bortezomib(硼替佐米)

Oncology(肿瘤)

arrow

Cabazitaxel(卡巴他赛)

Oncology(肿瘤)

arrow

Cabozantinib Hydrochloride(盐酸卡博替尼)

Oncology(肿瘤)

arrow

Cabozantinib S‑Malate(苹果酸卡博替尼)

Oncology(肿瘤)

arrow

Capecitabine(卡培他滨)

Oncology(肿瘤)

arrow

Carfilzomib(卡非佐米)

Oncology(肿瘤)

arrow

Decitabine(地西他滨)

Oncology(肿瘤)

arrow

Deucravacitinib(‌氘可来昔替尼)

Oncology(肿瘤)

arrow

Apalutamide (Amorphous and Form B)(阿帕他胺,无定形及 B晶 型)

Oncology(肿瘤)

arrow

Eribulin Mesylate(甲磺酸艾立布林)

Oncology(肿瘤)

arrow

Gemcitabine Hydrochloride(盐酸吉西他滨)

Oncology(肿瘤)

arrow

Lomustine(洛莫司汀)

Oncology(肿瘤)

arrow

Nilotinib Hydrochloride(盐酸尼洛替尼)

Oncology(肿瘤)

arrow

Olaparib (Form A)(奥拉帕利,A 晶型)

Oncology(肿瘤)

arrow

Palbociclib(哌柏西利)

Oncology(肿瘤)

arrow

Pazopanib(帕唑帕尼)

Oncology(肿瘤)

arrow

Pemetrexed Disodium Heptahydrate(培美曲塞二钠七水合物)

Oncology(肿瘤)

arrow

Pirtobrutinib(匹妥布替尼)

Oncology(肿瘤)

arrow

Relugolix(瑞卢戈利)

Oncology(肿瘤)

arrow

Pomalidomide(泊马度胺)

Oncology(肿瘤)

arrow

Acalabrutinib(阿卡替尼)

Oncology(肿瘤)

arrow

Capivasertib(卡帕塞替尼)

Oncology(肿瘤)

arrow

Lenalidomide (Form A)(来那度胺,A 晶型)

Oncology(肿瘤)

arrow

Midostaurin (Amorphous and Form II)(米哚妥林,无定形及 II 晶型)

Oncology(肿瘤)

arrow

Lenvatinib Mesylate (Form C and MIBK Solvate)(甲磺酸仑伐替尼,C 型及 MIBK 溶合物)

Oncology(肿瘤)

arrow

Enzalutamide(恩扎卢胺)

Oncology(肿瘤)

arrow

免责声明

No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.